Dermavant to recruit 30 patients in Phase IIa vitiligo trial

The Phase IIa trial will collect liquid from blisters to investigate whether cerdulatinib can reduce Chemokine, ligand 9 and CXCL10, which are upregulated during pigmentation abnormality in vitiligo patients.